ROCK2
ENSG00000134318
Target class
Kinase
Chromosome
2
Approved drugs
3
Clinical candidates (approved and in development)
12
- Approved drugs
- 3
- ClinGen gene-disease validity
- Limited
- Clinical candidates (approved and in development)
- 12
- Chemical probe available
- Yes
- Target name
- ROCK2
- Gene name
- Rho associated coiled-coil containing protein kinase 2
- Gene symbol
- ROCK2
- Protein name
- Rho-associated protein kinase 2 (EC 2.7.11.39) (Rho kinase 2) (Rho-associated, coiled-coil-containing protein kinase 2) (Rho-associated, coiled-coil-containing protein kinase II) (ROCK-II) (p164 ROCK-2)
- Gene biotype
- Protein coding
- Gene family
- Pleckstrin homology domain containing|Rho associated coiled-coil containing protein kinase family
- Target class
- Kinase
- Target type
- Human gene
- Tissues expressed in
- 54
- Protein localisation evidence grade
- Supported
- Highest tissue expression
- 61.42
- Tissue specificity (Gini)
- 0.352
- Tissue specificity (tau)
- 0.672
- KEGG gene identifiers
- hsa:9475
- Protein interaction confidence
- 0.889128
- Protein interaction partners
- 46
- R-HSA-3928662
- R-HSA-3928663
- R-HSA-416482
- R-HSA-416572
- R-HSA-4420097
- R-HSA-5627117
- R-HSA-8980692
- R-HSA-9013026
- R-HSA-9013106
- R-HSA-9013407
- R-HSA-9013422
- R-HSA-9679191
- End position
- 11348330
- Start position
- 11179759
- Chromosome
- 2
- Strand
- Reverse
- Cytoplasm. Cell membrane
- Peripheral membrane protein . Nucleus. Cytoplasm, cytoskeleton, microtubule organizing center, centrosome. Note=Cytoplasmic, and associated with actin microfilaments and the plasma membrane. .
- Cytosol
- Tissue specificity (tau)
- 0.672441
- Expression inequality (Gini)
- 0.35154
Expression in transcripts per million
- Artery - Tibial
- 61.42
- Adipose - Subcutaneous
- 46.93
- Uterus
- 44.61
- Artery - Aorta
- 43.62
- Artery - Coronary
- 42.12
Expression in transcripts per million
- Artery - Tibial61.42
- Adipose - Subcutaneous46.93
- Uterus44.61
- Artery - Aorta43.62
- Artery - Coronary42.12
- Brain - Cerebellar Hemisphere38.15
- Cells - Cultured fibroblasts36.76
- Lung36.35
- Bladder35.76
- Adipose - Visceral (Omentum)34.74
- Breast - Mammary Tissue33.32
- Brain - Cerebellum32.38
- Cervix - Endocervix32.11
- Esophagus - Muscularis31.95
- Fallopian Tube31.02
- Cervix - Ectocervix30.75
- Nerve - Tibial29.75
- Esophagus - Gastroesophageal Junction29.58
- Ovary23.71
- Muscle - Skeletal23.08
- Colon - Sigmoid22.62
- Colon - Transverse20.49
- Thyroid20.27
- Vagina20.14
- Spleen19.49
And 29 more, listed on the interactive page.
- GO:0006468
- GO:0006939
- GO:0007266
- GO:0016525
- GO:0030155
- GO:0030335
- GO:0032956
- GO:0044788
- GO:0045019
- GO:0045616
- GO:0051298
- GO:0051492
- GO:0051496
- GO:0051893
- GO:0072659
- GO:0150033
- GO:1902004
- GO:1902966
- GO:1902993
- GO:1903140
- GO:1903347
- GO:2000114
- GO:2000145
- GO:0005737
- GO:0005813
- GO:0005829
- GO:0036464
- GO:0002020
- GO:0003723
- GO:0004674
- GO:0005515
- GO:0061133
- GO:0072518
pulmonary hypertension
Effects
- Inhibition/Decrease/Downregulation
Studies
- clinical
Biological samples
- respiratory
PubMed 38773351GI disorder
Effects
- Inhibition/Decrease/Downregulation
Studies
- clinical
Biological samples
- GI
PubMed 38773351Anxiety
Effects
- Inhibition/Decrease/Downregulation
Studies
- clinical
Biological samples
- CNS
PubMed 38773351heart disease
Studies
- preclinical: Important for the heart and vasculature based on findings in genetically modified or kinase-inhibitor-treated mice. Role of kinase in heart/vasculature: Pro-fibrotic and pro-apoptotic in the setting of pressure overload
Biological samples
- cardiovascular system
PubMed 21283106nervous system disorder
Effects
- Activation/Increase/Upregulation
Studies
- clinical
Biological samples
- CNS
PubMed 38773351cardiac dysfunction
Effects
- Inhibition/Decrease/Downregulation
Studies
- clinical
Biological samples
- CV
PubMed 38773351lymphatic disorder
Effects
- Inhibition/Decrease/Downregulation
Studies
- clinical
Biological samples
- lymph
PubMed 38773351cytopenia
Effects
- Inhibition/Decrease/Downregulation
Studies
- clinical
Biological samples
- blood/bone marrow
PubMed 38773351Memory impairment
Effects
- Activation/Increase/Upregulation
Studies
- clinical
Biological samples
- CNS
PubMed 38773351
Related records
Trials (115)
- 24-hour Effect of Rocklatan Compared With Latanoprost in Open Angle Glaucoma and Ocular Hypertension Patients
- A 2-Part, Phase 2 Open-label and Crossover Study of Belumosudil for Treatment of Idiopathic Pulmonary Fibrosis
- A Clinical Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Belumosudil in Chinese Adolescents With cGVHD Who Have Had an Inadequate Response to Glucocorticoids or Other Systemic Therapies
- A Clinical Trial of Safety and Efficacy of Fasudil in Subjects With Amyotrophic Lateral Sclerosis (ALS)
- A Controlled Study of the Aqueous Humor Dynamics of AR-13324 Ophthalmic Solution in Healthy Adult Volunteers
- A Dose Titration Study to Assess the Effects of SAR407899 in Patients With MVA and/or Persistent Stable Angina Despite Angiographically Successful PCI
- A Multi-Center Study on the Use of Rho-Kinase Inhibitor to Reduce or Prevent PVR in RRD Eyes at High Risk for PVR
- A Phase 2 Study Evaluating the Safety and Efficacy of Netarsudil Ophthalmic Solution in Patients With Corneal Edema Due to Fuchs Corneal Dystrophy
- A Phase 2, Double-blind, Placebo-controlled Study of the Efficacy and Safety of Belumosudil in Subjects With Moderate/Severe Chronic Plaque Psoriasis
- A Rho-kinase Inhibitor (Fasudil) in the Treatment of Raynaud's Phenomenon
- A Safety and Tolerability Study of Belumosudil (KD025) Treatment in Subjects With Moderately Severe Psoriasis Vulgaris
- A Single Centre Study to Evaluate 3 Ophthalmic Formulations in Healthy Subjects
- A Study of Belumosudil in Children With Chronic Graft Versus Host Disease (schoolROCK)
- A Study of Belumosudil in People at Risk of Developing Graft-Versus-Host Disease After a Stem Cell Transplant
- A Study of Efficacy and Safety of PHP-201 in Patients With Primary Open Angle Glaucoma or Ocular Hypertension
- A Study to Assess the Effect of Oral Belumosudil on Inhibition of Various Proteins in the Fed State in Healthy Male Subjects
- A Study to Determine the Effect of 500 mg Oral Dose of KD025 in Healthy Male and Post-menopausal Female Subjects
- A Study to Determine the Effect of Multiple Oral Doses and Regimens of KD025 in Healthy Male and Post-menopausal Female Subjects
- A Study to Determine the Effect of Multiple Oral Doses of SLx-2119 in Healthy Male Subjects
- A Study to Evaluate the Safety and Efficacy of K-321 Eye Drops After Descemetorhexis in Participants With Fuchs Endothelial Corneal Dystrophy (FECD)
Drugs (14)
- AMA0076 Rho-associated protein kinase inhibitor
- AT-13148 Rho-associated protein kinase inhibitor
- Belumosudil Rho-associated protein kinase 2 inhibitor
- Belumosudil mesylate Rho-associated protein kinase inhibitor
- DE-104 Rho-associated protein kinase inhibitor
- Fasudil Rho-associated protein kinase inhibitor
- Netarsudil Rho-associated protein kinase inhibitor
- Netarsudil dimesylate Rho-associated protein kinase inhibitor
- Ripasudil Rho-associated protein kinase inhibitor
- Ripasudil hydrochloride dihydrate Rho-associated protein kinase inhibitor
- SAR-407899 Rho-associated protein kinase inhibitor
- SAR-407899 FREE BASE Rho-associated protein kinase inhibitor
- Verosudil Rho-associated protein kinase inhibitor
- Y-39983 Rho-associated protein kinase inhibitor